Advertisement Covers CROI 2017


Antibodies Could Offer a More 'Natural' and Safer HIV Treatment or Prevention Option

February 13, 2017

In addition to developing and manufacturing synthetic drugs to treat and prevent HIV, researchers are working on ways to use our own immune systems to fight and prevent HIV infection. Broadly neutralizing antibodies, which are produced by the immune system of some people living with HIV, may be part of one such strategy.

In a CROI session today about advances in antibody treatments for HIV prevention and treatment, Richard Kroup, M.D., from NIAID provided an overview of the recent advances in the field -- and what antibodies could mean for future vaccine and HIV treatment options.

"I like to think there's a reasonable likelihood that antibodies will work [for prevention]," said Koup. "There's a good safety record with monoclonal antibodies for other targets, and the potential that a single shot could confer long-lasting protection for three to six months."

This excerpt was cross-posted with the permission of Read the full article.

Related Stories

Return of the Antibodies: A Top HIV Clinical Development of 2016
NIH Scientists Identify Potent Antibody That Neutralizes Nearly All HIV Strains

This article was provided by BETA. Visit their website at

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.